| Literature DB >> 28911061 |
G Murphy1, V McCormack2, B Abedi-Ardekani3, M Arnold4, M C Camargo1, N A Dar5, S M Dawsey1, A Etemadi1, R C Fitzgerald6, D E Fleischer7, N D Freedman1, A M Goldstein1, S Gopal8, M Hashemian1,9, N Hu1, P L Hyland1, B Kaimila8, F Kamangar10, R Malekzadeh9, C G Mathew11,12, D Menya13, G Mulima8, M M Mwachiro14, A Mwasamwaja15, N Pritchett1, Y-L Qiao16, L F Ribeiro-Pinto17, M Ricciardone18, J Schüz2, F Sitas19,20, P R Taylor1, K Van Loon21, S-M Wang1,16, W-Q Wei16, C P Wild22, C Wu16, C C Abnet1, S J Chanock1, P Brennan3.
Abstract
The International Agency for Research on Cancer (IARC) and the US National Cancer Institute (NCI) have initiated a series of cancer-focused seminars [Scelo G, Hofmann JN, Banks RE et al. International cancer seminars: a focus on kidney cancer. Ann Oncol 2016; 27(8): 1382-1385]. In this, the second seminar, IARC and NCI convened a workshop in order to examine the state of the current science on esophageal squamous cell carcinoma etiology, genetics, early detection, treatment, and palliation, was reviewed to identify the most critical open research questions. The results of these discussions were summarized by formulating a series of 'difficult questions', which should inform and prioritize future research efforts. Published by Oxford University Press on behalf of the European Society for Medical Oncology 2017. This work is written by US Government employees and is in the public domain in the US.Entities:
Keywords: clinical research; early detection; epidemiology; esophageal squamous cell carcinoma (ESCC); genomics
Mesh：
Year: 2017 PMID： 28911061 PMCID： PMC5834011 DOI： 10.1093/annonc/mdx279
Source DB: PubMed Journal: Ann Oncol ISSN： 0923-7534 Impact factor: 32.976